Skip to main content
Top
Published in: Inflammation Research 12/2009

01-12-2009 | Original Research Paper

Effects of high-dose corticosteroids on post-traumatic inflammatory mediators

Authors: Olav Reikerås, Arthur Helle, Claus Danckert Krohn, Jens Ivar Brox

Published in: Inflammation Research | Issue 12/2009

Login to get access

Abstract

Objective

Plasma concentrations of inflammatory mediators are substantially increased in major orthopaedic surgery. It was our hypothesis that corticosteroids would reduce the post-operative levels of inflammatory mediators in patients with ankylosing spondylitis, and we performed a single-centre randomised controlled trial.

Patients and methods

In 20 consecutive patients, an osteotomy of the lumbar spine was done. By concealed random allocation, 10 of the patients were given 10 mg/kg of methylprednisolone pre-operatively. The control patients received the same amount of saline. Samples of arterial blood and local blood from the surgical site were sampled and analysed for inflammatory cytokines and prostaglandin E2.

Results

There were significant increments in systemic levels of IL-6, IL-10 and sTNF-R1. Corticosteroids significantly reduced the increases of IL-6 and significantly increased the levels of IL-10 and sTNF-R1. Locally, the expressions of TNF-α, IL-1β, IL-6 and sTNF-R1 were significantly increased in both groups post-operatively. Corticosteroids significantly increased the local expressions of IL-10 and sTNF-R1. There were significantly higher local than systemic levels of inflammatory mediators except for TNF-α.

Conclusion

This study shows that in traumatic injury there are generally higher local than systemic expressions of inflammatory mediators, and that the main anti-inflammatory effects of high-dose corticosteroids are suppression of systemic IL-6 and increased expressions of IL-10 and sTNF-R1, both systemically and locally.
Literature
1.
go back to reference Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002;Suppl 3:iii8–iii18. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002;Suppl 3:iii8–iii18.
2.
go back to reference Keller C, Webb A, Davies J. Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review. Ann Rheum Dis. 2003;62:1128–32.CrossRefPubMed Keller C, Webb A, Davies J. Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review. Ann Rheum Dis. 2003;62:1128–32.CrossRefPubMed
3.
go back to reference Sonel B, Tutkak H, Duzgun N. Serum levels of Il-1 beta, TNF-alpha, Il-8, and acute phase proteins in seronegative spondyloarthropathies. Joint Bone Spine. 2002;69:463–8.CrossRefPubMed Sonel B, Tutkak H, Duzgun N. Serum levels of Il-1 beta, TNF-alpha, Il-8, and acute phase proteins in seronegative spondyloarthropathies. Joint Bone Spine. 2002;69:463–8.CrossRefPubMed
4.
go back to reference Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995;38:499–505.CrossRefPubMed Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995;38:499–505.CrossRefPubMed
5.
go back to reference Francois RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis. 2006;65:713–20.CrossRefPubMed Francois RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis. 2006;65:713–20.CrossRefPubMed
6.
go back to reference Lange U, Teichmann J, Stracke H. Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. Eur J Med Res. 2000;5:507–11.PubMed Lange U, Teichmann J, Stracke H. Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. Eur J Med Res. 2000;5:507–11.PubMed
7.
go back to reference Drouart M, Saas P, Billot M, Cedoz JP, Tiberghien P, Wendling D. High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol. 2003;132:158–62.CrossRefPubMed Drouart M, Saas P, Billot M, Cedoz JP, Tiberghien P, Wendling D. High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol. 2003;132:158–62.CrossRefPubMed
8.
go back to reference Sieper J, Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 years of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology. 2005;44:1525–30.CrossRefPubMed Sieper J, Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 years of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology. 2005;44:1525–30.CrossRefPubMed
9.
go back to reference Braun J, Landewe R, Hermann KG, Han J, Yan S, Williamson P. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum. 2006;54:1646–52.CrossRefPubMed Braun J, Landewe R, Hermann KG, Han J, Yan S, Williamson P. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum. 2006;54:1646–52.CrossRefPubMed
10.
go back to reference Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosisng spondylitis after treatment with infliximab. J Ann Rheum Dis. 2008;67:511–7.CrossRef Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosisng spondylitis after treatment with infliximab. J Ann Rheum Dis. 2008;67:511–7.CrossRef
11.
go back to reference Schleimer RP. An overview of glucocorticoid anti-inflammatory actions. Eur J Clin Pharmacol. 1993;45:S3–7.CrossRefPubMed Schleimer RP. An overview of glucocorticoid anti-inflammatory actions. Eur J Clin Pharmacol. 1993;45:S3–7.CrossRefPubMed
12.
go back to reference Skjelbred P, Løkken P. Reduction of pain and swelling by a corticosteroid. Eur J Clin Pharmacol. 1982;21:391–6.CrossRefPubMed Skjelbred P, Løkken P. Reduction of pain and swelling by a corticosteroid. Eur J Clin Pharmacol. 1982;21:391–6.CrossRefPubMed
13.
go back to reference Holte K, Kehlet H. Perioperative single-dose glucocorticoid administration: pathophysiologic effects and clinical implications. J Am Coll Surg. 2002;195:694–712.CrossRefPubMed Holte K, Kehlet H. Perioperative single-dose glucocorticoid administration: pathophysiologic effects and clinical implications. J Am Coll Surg. 2002;195:694–712.CrossRefPubMed
14.
go back to reference Bisgaard T, Klarskov B, Kehlet H, Rosenberg J. Preoperative dexamethasone improves surgical outcome after laparoscopic cholecystectomy. A randomized double-blind placebo-controlled trial. Ann Surg. 2003;238:651–60.CrossRefPubMed Bisgaard T, Klarskov B, Kehlet H, Rosenberg J. Preoperative dexamethasone improves surgical outcome after laparoscopic cholecystectomy. A randomized double-blind placebo-controlled trial. Ann Surg. 2003;238:651–60.CrossRefPubMed
15.
go back to reference Lundin A, Magnuson A, Axelsson K, Kogler H, Samuelsson L. The effect of perioperative corticosteroids on the outcome of microscopic lumbar disc surgery. Eur Spine J. 2003;12:625–30.CrossRefPubMed Lundin A, Magnuson A, Axelsson K, Kogler H, Samuelsson L. The effect of perioperative corticosteroids on the outcome of microscopic lumbar disc surgery. Eur Spine J. 2003;12:625–30.CrossRefPubMed
16.
go back to reference Ferreira SH, Cunha FQ, Lorenzetti FB. Role of lipocortin-1 in the anti-hyperalgesic actions of dexamethasone. Br J Pharmacol. 1997;121:883–8.CrossRefPubMed Ferreira SH, Cunha FQ, Lorenzetti FB. Role of lipocortin-1 in the anti-hyperalgesic actions of dexamethasone. Br J Pharmacol. 1997;121:883–8.CrossRefPubMed
17.
go back to reference Baigrie RJ, Lamont PM, Kwiatkowski D, Dallman MJ, Morris PJ. Systemic cytokine response after major surgery. Br J Surg. 1992;79(8):757–60.CrossRefPubMed Baigrie RJ, Lamont PM, Kwiatkowski D, Dallman MJ, Morris PJ. Systemic cytokine response after major surgery. Br J Surg. 1992;79(8):757–60.CrossRefPubMed
18.
go back to reference Garret S, Jenkins T, Kennedy LG. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286–91. Garret S, Jenkins T, Kennedy LG. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286–91.
19.
go back to reference Calin A, Garret S, Whitelock H. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281–5.PubMed Calin A, Garret S, Whitelock H. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281–5.PubMed
20.
go back to reference Kennedy LG, Jenkinson TR, Mallorie PA, Whitelock HC, Barret SL, Calin A. Ankylosing spondylitis: the correlation between metrology score and radiology. Br J Rheumatol. 1995;34:767–71.CrossRefPubMed Kennedy LG, Jenkinson TR, Mallorie PA, Whitelock HC, Barret SL, Calin A. Ankylosing spondylitis: the correlation between metrology score and radiology. Br J Rheumatol. 1995;34:767–71.CrossRefPubMed
21.
go back to reference Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med. 1976;84:304–15.PubMed Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med. 1976;84:304–15.PubMed
22.
go back to reference Braun J, Bollow M, Seyrekbasan F, Häberle HJ, Eggens U, Mertz A, et al. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol. 1996;23:659–64.PubMed Braun J, Bollow M, Seyrekbasan F, Häberle HJ, Eggens U, Mertz A, et al. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol. 1996;23:659–64.PubMed
23.
go back to reference af Klint E, Grundtman C, Engström M, Catrina AI, Makrygiannakis D, Klareskog L, et al. Intraarticular glucocorticoid treatment reduces inflammation in synovial cell infiltrations more efficiently than in synovial blood vessels. Arthritis Rheum. 2009;52:3880–9.CrossRef af Klint E, Grundtman C, Engström M, Catrina AI, Makrygiannakis D, Klareskog L, et al. Intraarticular glucocorticoid treatment reduces inflammation in synovial cell infiltrations more efficiently than in synovial blood vessels. Arthritis Rheum. 2009;52:3880–9.CrossRef
24.
go back to reference Youssef PP, Haynes DR, Triantafillou S, Parker A, Gamble JR, Roberts-Thomson PJ. Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis. Arthritis Rheum. 1997;40:1400–8.CrossRefPubMed Youssef PP, Haynes DR, Triantafillou S, Parker A, Gamble JR, Roberts-Thomson PJ. Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis. Arthritis Rheum. 1997;40:1400–8.CrossRefPubMed
25.
go back to reference Sauerland S, Nagelschmidt M, Mallmann P, Neugebeuer EA. Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a systematic review. Drug Saf. 2000;23:449–61.CrossRefPubMed Sauerland S, Nagelschmidt M, Mallmann P, Neugebeuer EA. Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a systematic review. Drug Saf. 2000;23:449–61.CrossRefPubMed
26.
go back to reference Gilron I, Milne B, Hong M. Cyclooxygenase-2 inhibitors in postoperative pain management. Current evidence and future directions. Anesthesiology. 2003;99:1198–208.CrossRefPubMed Gilron I, Milne B, Hong M. Cyclooxygenase-2 inhibitors in postoperative pain management. Current evidence and future directions. Anesthesiology. 2003;99:1198–208.CrossRefPubMed
27.
go back to reference Fereira SH, Lorenzetti BB, Poole S. Bradykinin initiates cytokine mediated inflammatory hyperalgesia. Br J Phamacol. 1993;110:127–31. Fereira SH, Lorenzetti BB, Poole S. Bradykinin initiates cytokine mediated inflammatory hyperalgesia. Br J Phamacol. 1993;110:127–31.
28.
go back to reference Baton BE, Jakaway JP, Smith SR, Siegel MI. Cytokine inhibition by a novel steroid, mometasone furoate. Immunopharmacol Immunotoxicol. 1991;13:251–61.CrossRef Baton BE, Jakaway JP, Smith SR, Siegel MI. Cytokine inhibition by a novel steroid, mometasone furoate. Immunopharmacol Immunotoxicol. 1991;13:251–61.CrossRef
29.
go back to reference Liberman AC, Druker J, Perone MJ, Arzt E. Glucocorticoids in the regulation of transcription factors that control cytokine synthesis. Cytokine Growth Factor Rev. 2007;18:45–56.CrossRefPubMed Liberman AC, Druker J, Perone MJ, Arzt E. Glucocorticoids in the regulation of transcription factors that control cytokine synthesis. Cytokine Growth Factor Rev. 2007;18:45–56.CrossRefPubMed
30.
go back to reference Scheinman RI, Cogwell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;13(270):232–3. Scheinman RI, Cogwell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;13(270):232–3.
31.
go back to reference Scheinman RI, Gualberto A, Jewll CM, Cidlowski JA, Baldwin AS. Characterization of mechanisms involved in transpression of NF-kappa B by activated glucoid receptors. Cell Mol Biol. 1995;15:943–53. Scheinman RI, Gualberto A, Jewll CM, Cidlowski JA, Baldwin AS. Characterization of mechanisms involved in transpression of NF-kappa B by activated glucoid receptors. Cell Mol Biol. 1995;15:943–53.
32.
go back to reference Adcock IM, Shirasaki H, Gelder CM. The effect of glucocorticoids on phorbol ester and cytokine stimulated transcription factor activation in human lung. Life Sci. 1994;55:1147–53.CrossRefPubMed Adcock IM, Shirasaki H, Gelder CM. The effect of glucocorticoids on phorbol ester and cytokine stimulated transcription factor activation in human lung. Life Sci. 1994;55:1147–53.CrossRefPubMed
33.
go back to reference Barnes PJ, Karin M. Mechanism of disease: nuclear factor-[kappa]B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;15:1066–71.CrossRef Barnes PJ, Karin M. Mechanism of disease: nuclear factor-[kappa]B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;15:1066–71.CrossRef
34.
go back to reference Krohn CD, Reikerås O, Aasen AO. The cytokines IL-1beta and IL-1 receptor antagonist, IL-2 and IL-2 soluble receptor-alpha, IL-6 and IL-6 soluble receptor, TNF-alpha and TNF soluble receptor I, and IL10 in drained and systemic blood after major orthopaedic surgery. Eur J Surg. 1999;165:101–9.CrossRefPubMed Krohn CD, Reikerås O, Aasen AO. The cytokines IL-1beta and IL-1 receptor antagonist, IL-2 and IL-2 soluble receptor-alpha, IL-6 and IL-6 soluble receptor, TNF-alpha and TNF soluble receptor I, and IL10 in drained and systemic blood after major orthopaedic surgery. Eur J Surg. 1999;165:101–9.CrossRefPubMed
35.
go back to reference Clementsen T, Krohn CD, Reikerås O. Systemic and local cytokine patterns during total hip surgery. Scand J Clin Lab Invest. 2006;66:535–42.CrossRefPubMed Clementsen T, Krohn CD, Reikerås O. Systemic and local cytokine patterns during total hip surgery. Scand J Clin Lab Invest. 2006;66:535–42.CrossRefPubMed
36.
go back to reference Kotake S, Sato K, Kim KJ. Interleukin-6 and soluble interleukin-6 in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 1996;11:88–95.PubMedCrossRef Kotake S, Sato K, Kim KJ. Interleukin-6 and soluble interleukin-6 in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 1996;11:88–95.PubMedCrossRef
37.
go back to reference Okamoto H, Yamamura M, Morita Y. The synovial expression and blood levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum. 1997;40:1096–105.CrossRefPubMed Okamoto H, Yamamura M, Morita Y. The synovial expression and blood levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum. 1997;40:1096–105.CrossRefPubMed
38.
go back to reference Steensberg A, Fischer CP, Keller C, Kirsten Møller, Pedersen BK. Il-6 enhances plasma Il-1ra, Il-10, and cortisol in humans. Am J Physiol Endocrinol Metab. 2003;285:E433–7.PubMed Steensberg A, Fischer CP, Keller C, Kirsten Møller, Pedersen BK. Il-6 enhances plasma Il-1ra, Il-10, and cortisol in humans. Am J Physiol Endocrinol Metab. 2003;285:E433–7.PubMed
39.
go back to reference Waage A, Slupphaug G, Shalaby R. Glucocorticoids inhibit the production of IL6 from monocytes, endothelial cells and fibroblasts. Eur J Immunol. 1990;20:2439–43.CrossRefPubMed Waage A, Slupphaug G, Shalaby R. Glucocorticoids inhibit the production of IL6 from monocytes, endothelial cells and fibroblasts. Eur J Immunol. 1990;20:2439–43.CrossRefPubMed
40.
go back to reference Fantuzzi G, Ghezzi P. Glucocorticoids as cytokine inhibitors: role in neuroendocrine control and therapy of inflammatory diseases. Mediators Inflamm. 1993;2:263–70.CrossRefPubMed Fantuzzi G, Ghezzi P. Glucocorticoids as cytokine inhibitors: role in neuroendocrine control and therapy of inflammatory diseases. Mediators Inflamm. 1993;2:263–70.CrossRefPubMed
41.
go back to reference Høgevold HE, Kierulf P, Ovstebø R, Reikerås O. Acute phase reactant and interleukin 6 after total hip replacement. Effects of high dose corticosteroids. Eur J Surg. 1992;158:339–45.PubMed Høgevold HE, Kierulf P, Ovstebø R, Reikerås O. Acute phase reactant and interleukin 6 after total hip replacement. Effects of high dose corticosteroids. Eur J Surg. 1992;158:339–45.PubMed
42.
go back to reference Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994;83:113–8.PubMed Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994;83:113–8.PubMed
43.
go back to reference Sheeran P, Hall GM. Cytokines in anaesthesia. Br J Anaesth. 1997;78:201–19.PubMed Sheeran P, Hall GM. Cytokines in anaesthesia. Br J Anaesth. 1997;78:201–19.PubMed
44.
go back to reference Ayala A, Lehman DL, Herdon CD, Chaudry IH. Mechanism of enhanced susceptibility to sepsis following hemorrhage: interleukin-10 suppression of T-cell response is mediated by eicosanoid-induced interleukin-4 release. Arch Surg. 1994;129:1172–8.PubMed Ayala A, Lehman DL, Herdon CD, Chaudry IH. Mechanism of enhanced susceptibility to sepsis following hemorrhage: interleukin-10 suppression of T-cell response is mediated by eicosanoid-induced interleukin-4 release. Arch Surg. 1994;129:1172–8.PubMed
45.
go back to reference Barber AE, Coyle SM, Marano MA, Fischer E, Calvano SE, Fong Y, et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol. 1993;150:1999–2006.PubMed Barber AE, Coyle SM, Marano MA, Fischer E, Calvano SE, Fong Y, et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol. 1993;150:1999–2006.PubMed
46.
go back to reference Dandona P, Aljada A, Garg R, Mohanty P. Increase in plasma Interleukin–10 following hydrocortisone injection. J Clin Endocinol Metab. 1999;84:1141–4.CrossRef Dandona P, Aljada A, Garg R, Mohanty P. Increase in plasma Interleukin–10 following hydrocortisone injection. J Clin Endocinol Metab. 1999;84:1141–4.CrossRef
Metadata
Title
Effects of high-dose corticosteroids on post-traumatic inflammatory mediators
Authors
Olav Reikerås
Arthur Helle
Claus Danckert Krohn
Jens Ivar Brox
Publication date
01-12-2009
Publisher
SP Birkhäuser Verlag Basel
Published in
Inflammation Research / Issue 12/2009
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-009-0061-3

Other articles of this Issue 12/2009

Inflammation Research 12/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.